Overview. Endotoxin testing is not a routine substitute for microbiological enumeration in non-sterile cannabis products. It becomes relevant where the route of administration and manufacturing process create a pyrogen risk, particularly for parenteral or certain sterile cannabis-derived products. The test strategy must be linked to product use, process water and patient exposure.
When endotoxin testing is relevant
The need for testing depends on dosage form and route. Oral oils and dried flower are generally controlled through non-sterile microbiological specifications, while parenteral or sterile investigational products may require endotoxin limits. Process intermediates may also need monitoring where endotoxin could carry into a sterile product.
Assay technologies
Gel-clot, kinetic turbidimetric and chromogenic methods are established approaches. Recombinant factor C methods may be considered where accepted. Method selection should reflect sensitivity, matrix colour, automation and regulatory expectations.
Product interference
Cannabinoids, solvents, surfactants, colours and oils may inhibit or enhance the lysate reaction. Method suitability determines a non-interfering dilution while maintaining enough sensitivity to meet the endotoxin limit.
Controls and system suitability
Standard curves, reagent blanks, positive product controls and endotoxin-free consumables are essential. Failure of a positive product control may indicate inhibition rather than absence of endotoxin.
Sampling and hold time
Samples should be representative and protected from contamination. Hold times and storage conditions must be established because adsorption or degradation can affect recovery.
Investigation of unexpected results
Investigations should review water systems, cleaning, sample handling, dilution, reagent preparation, equipment and process history. Retesting should address a defined hypothesis rather than search for a passing result.
Practical reference table
| Method | Output | Strength | Main limitation |
|---|---|---|---|
| Gel clot | Pass/fail endpoint | Simple and robust | Limited quantitative information |
| Kinetic turbidimetric | Quantitative curve | Automation and broad range | Matrix turbidity may interfere |
| Chromogenic | Colour-based response | High sensitivity | Colour interference possible |
| Recombinant factor C | Fluorescent response | Non-animal reagent | Acceptance depends on framework |
Control and decision path
Frequently asked questions
Does all medical cannabis require endotoxin testing?
No. The requirement depends mainly on route of administration and product type.
What is a positive product control?
A spiked sample used to demonstrate that the product matrix does not inhibit or enhance the assay.
Can endotoxin testing replace sterility testing?
No. They measure different hazards.
Why are oils difficult to test?
They may interfere with dispersion, reaction kinetics and optical detection.
When should recombinant factor C be used?
When scientifically suitable and accepted under the applicable regulatory and pharmacopoeial framework.
Primary references and guidance
- European Pharmacopoeia 2.6.14, Bacterial Endotoxins
- USP <85>
- EU GMP Annex 1
- ICH Q6A
- FDA Guidance on Pyrogen and Endotoxins Testing
- EU GMP Part I, Chapter 6
- ISO 17025
Confirm the current effective revision and national applicability before operational or regulatory use.